Skip to content
Bored Studies
RecruitingAccepts healthy volunteersEarly Phase 1

Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy

Texas Tech University Health Sciences Center · NCT06349772

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Early Phase 1
Target enrollment
130
US sites recruiting
1
Study start
November 1, 2024
Record last updated
July 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two extended local anesthesia strategies currently approved by FDA and on the market for post-surgical pain control. The investigators plan on randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively both in the hospital and at home. The investigators will measure the outcome of two drugs, Zynrelief, and Exparel on postoperative pain score -using the NRS pin score up to 72 hours after surgery. The total opioid use will be recorded in forms that will be used to measure pain score and total opioid use and will be collected to the Excel sheet. The cost of the drug will be calculated for internal use for Hospital purpose only.

Being studied: Zynrelef; Exparel

Conditions: Post Operative Pain

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age range: 18-65 years old
  • Scheduled or being scheduled to undergo robotic sleeve gastrectomy by Dr. Goyal.
  • Is able to provide written informed consent.
  • Is able to adhere to the study visit schedule and complete all study assessments.

Exclusion Criteria

  • Positive urine drug screen prior to surgery
  • History of substance abuse in the past year-by self report
  • Patient with ongoing daily narcotic use at the time of surgery-by self report
  • Inability to understand informed consent or read English/Spanish
  • Pregnant or lactating patients
  • Prisoners
  • Patients with renal or hepatic failure
  • Bupivacaine use within 96 hours of operation
  • Patient intolerant of opiates, nonsteroidal anti-inflammatory drug s, acetaminophen, or Zynrelef and Exparel. Subjects in all cohorts must not have any contraindications to any of the protocol-specified drugs
  • Patient with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients

Recruiting US locations

  • Texas Tech University Health Sciences Center

    Lubbock, TX 79430

    Site contact: Chad Copeland · 806-743-6239 · CHADLEY.COPELAND@TTUHSC.EDU

Study contacts (from the official record)

  • Tommy Wright, DO · 8176888021 · tommy.wright@ttuhsc.edu
  • Vinay Goyal, MD · vinay.goyal@ttuhsc.edu
All pain studies in Texas →
Zynrelef vs Exparel: The Battle of Postoperative Pain Control… (NCT06349772) | Bored Studies